$482.28
2.53% yesterday
Nasdaq, Feb 04, 10:12 pm CET
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Vertex Pharmaceuticals Stock price

$482.28
+79.79 19.82% 1M
+5.37 1.13% 6M
+79.58 19.76% YTD
+53.39 12.45% 1Y
+240.32 99.32% 3Y
+242.62 101.24% 5Y
+373.01 341.37% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+11.91 2.53%
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Key metrics

Market capitalization $124.20b
Enterprise Value $119.37b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.24
P/S ratio (TTM) P/S ratio 11.70
P/B ratio (TTM) P/B ratio 7.95
Revenue growth (TTM) Revenue growth 10.96%
Revenue (TTM) Revenue $10.62b
EBIT (operating result TTM) EBIT $-307.80m
Free Cash Flow (TTM) Free Cash Flow $-1.11b
Cash position $6.53b
EPS (TTM) EPS $-1.99
P/E forward negative
P/S forward 11.40
EV/Sales forward 10.96
Short interest 1.71%
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a Vertex Pharmaceuticals forecast:

22x Buy
61%
11x Hold
31%
3x Sell
8%

Analyst Opinions

36 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
61%
Hold
31%
Sell
8%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10,617 10,617
11% 11%
100%
- Direct Costs 1,475 1,475
25% 25%
14%
9,142 9,142
9% 9%
86%
- Selling and Administrative Expenses 1,236 1,236
42% 42%
12%
- Research and Development Expense 7,994 7,994
126% 126%
75%
-88 -88
102% 102%
-1%
- Depreciation and Amortization 220 220
37% 37%
2%
EBIT (Operating Income) EBIT -308 -308
108% 108%
-3%
Net Profit -480 -480
114% 114%
-5%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Positive
The Motley Fool
one day ago
Vertex Pharmaceuticals (VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.
Positive
The Motley Fool
2 days ago
Some people are fair-weather friends; others are lifelong. It's a similar story with stocks.
Positive
The Motley Fool
3 days ago
Vertex Pharmaceuticals (VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 5,400
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today